FDA DTC Ad Study: Firms Win Small Concession; Viewings Will Be Less Dense
AbbVie, Valeant and Lilly had critiqued proposed study to assess impact of repeated exposure to direct-to-consumer drug ads on perception of risks and benefits.
AbbVie, Valeant and Lilly had critiqued proposed study to assess impact of repeated exposure to direct-to-consumer drug ads on perception of risks and benefits.